Last updated: March 11, 2026
What is NDC 43547-0441?
NDC 43547-0441 is a prescription drug identified by the National Drug Code (NDC) number. Based on publicly available databases, this NDC corresponds to Fostamatinib Disodium Hexahydrate (brand name: Tavneos), approved by the U.S. Food and Drug Administration (FDA) in 2021 for treating vasculitis.
Market Entry and Current Commercial Landscape
Indications and Market Size
Fostamatinib is indicated for adult patients with certain autoimmune vasculitis conditions when other therapies have failed. The targeted patient population is relatively small but significant given the high unmet need in rare autoimmune diseases.
| Population Segment |
Estimated Patients (U.S.) |
Growth Rate |
Notes |
| Vasculitis patients |
15,000–20,000 |
2–4% annually |
Based on prevalence data for ANCA-associated vasculitis (AAV) from NIH studies[1]. |
| Autoimmune disease prevalence |
4 million in U.S. |
1–2% |
General autoimmune conditions, though off-label use varies. |
Competitive Landscape
Fostamatinib competes with other immunosuppressants and biologics for vasculitis treatment. Existing therapies such as rituximab and corticosteroids have established market shares but come with limitations including safety profiles and administration routes.
| Major competitors |
Market share (est.) |
Key features |
Approval date |
| Rituximab |
50% |
Monoclonal antibody, IV infusion |
1997 (Rituxan) |
| Cyclophosphamide |
25% |
Chemotherapy agent |
1959 |
| Methotrexate |
15% |
Oral/injectable |
1950s |
Fostamatinib’s unique mechanism of action via spleen tyrosine kinase (Syk) inhibition offers potential advantages but faces challenges in market penetration due to existing therapies' entrenched positions.
Price Projections and Revenue Potential
Current Pricing
As of Q1 2023, the wholesale acquisition cost (WAC) for Fostamatinib (Tavneos) is approximately:
- $7,500 per 30-tablet bottle (each tablet 100 mg)
- Approximate annual treatment cost per patient: $30,000, accounting for typical dosing (100 mg twice daily).
Price Differentiation Factors
- Insurance Coverage: Insurance reimbursement policies influence net prices.
- Negotiated Discounts: PBMs typically negotiate discounts of 20-30%, reducing the net price for payers.
- Patient Assistance Programs: These can reduce out-of-pocket costs, impacting market penetration.
Market Penetration and Revenue Estimates (2023–2027)
Assuming gradual increased acceptance, the following projections are based on five-year compounded growth rates:
| Year |
Estimated Patients |
Market Adoption Rate |
Gross Revenue |
Notes |
| 2023 |
1,000 |
5% of total estimated target |
$30 million |
Initial adoption phase. |
| 2024 |
2,500 |
12.5% |
$75 million |
Expansion into specialty practices. |
| 2025 |
4,500 |
22.5% |
$135 million |
Growing clinician familiarity. |
| 2026 |
8,000 |
40% |
$240 million |
Increased patient access; potential label expansion. |
| 2027 |
10,000 |
50% |
$300 million |
Maximal penetration within target population. |
Price Sensitivity
Market entry strategies, competition, and payer negotiations likely will constrain the achievable net price per patient. Real-world revenue could be 10-20% lower than gross projections if significant discounts or variable reimbursement levels are applied.
Key Market Challenges
- Limited Patient Population: The rare disease focus restricts revenue potential.
- Pricing Pressures: Payers demand discounts and prefer established therapies.
- Competition: Biologics with proven efficacy possess higher market inertia.
- Regulatory Hurdles: Future label expansions might increase eligible patient counts but require additional trials and approvals.
Potential for Price Adjustment
Market exclusivity extends five years post-approval; subsequent biosimilar or generic entrants could reduce prices. Pending patent expirations, price erosion could be significant after 2026.
Summary of Market Dynamics
| Aspect |
Detail |
| Market size |
15,000–20,000 U.S. patients for vasculitis; broader autoimmune possibilities. |
| Competitive position |
Niche, with current reliance on biologics and immunosuppressants. |
| Price projection |
$30,000 annually per patient initially; potential decrease with discounts and biosimilars. |
| Revenue estimate |
$30–300 million over five years, depending on adoption rate and market penetration. |
Closing Remarks
Fostamatinib (NDC 43547-0441) is positioned as a niche therapy with limited but targeted revenue prospects. Market success hinges on clinical differentiation, payer reimbursement, and expanding indications.
Key Takeaways
- The U.S. market for Fostamatinib in vasculitis is small but growing, with an estimated maximum revenue of around $300 million annually.
- Current wholesale pricing approximates $7,500 per month; net prices after discounts are lower.
- Increasing clinician familiarity and label expansions could improve market share.
- Biosimilar competition and patent expirations after 2026 could depress prices and profits.
- Clinical differentiation over existing immunosuppressants remains critical for growth.
FAQs
Q1: What is the primary indication for NDC 43547-0441?
A1: It treats vasculitis, specifically ANCA-associated vasculitis, in adults who have failed other therapies.
Q2: What are the main competitors?
A2: Rituximab, cyclophosphamide, and methotrexate.
Q3: How is the drug priced?
A3: Wholesale acquisition cost is about $7,500 per 30-tablet bottle; net prices depend on negotiations and discounts.
Q4: What is the market potential?
A4: Up to $300 million annually in the U.S. with full adoption, considering the small patient base.
Q5: When do biosimilar or generic competitors threaten this market?
A5: Post patent expiration, expected around 2026, which could lead to substantial price declines.
References
[1] National Institutes of Health. (2020). Prevalence and incidence of vasculitis. NIH Publications.
